Rheumatology Diagnostics Laboratory (RDL), Los Angeles, has adopted the Cira multiplex platform from Aushon BioSystems, Billerica, Mass, as part of a strategic collaboration between the two companies.
Under the partnership, RDL will use the highly sensitive Cira platform to measure panels of protein biomarkers simultaneously for early detection and measurement of changes in disease activity for several autoimmune conditions. In addition, RDL will offer Aushon’s full test menu as part of its newly expanded contract research services, while also developing its own diagnostic assays using the Aushon platform.
Dmitry Karayev, MD, Rheumatology Diagnostics Laboratory.
“Our collaboration with Aushon will advance our development of diagnostics with a high degree of precision and sensitivity in assays using multiple protein measurements,” says Dmitry Karayev, MD, laboratory director at RDL. “The ability to accurately and reproducibly measure small changes in multiple proteins opens up new possibilities for diagnostics in complex disease.”
Aushon’s Cira platform enables the simultaneous measurement of up to 12 biomarkers at ultrasensitive detection levels and has been validated to meet the performance requirements for use in clinical and biopharma research applications.
Susan Vogt, Aushon BioSystems.
“We are delighted to collaborate with RDL and assist them as they expand their testing services, and in the development of new assays which can help patients live healthier lives,” says Susan Vogt, CEO of Aushon BioSystems. “We believe our platform will continue to play an important role in precision medicine advancing the use of biomarker profiles in diagnostics.”
For more information, visit Aushon BioSystems or RDL.
